Reneo Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 6,875,000 shares of its common stock at a public offering price of $8.00 per share for aggregate gross proceeds of approximately $55.0 million, before deducting underwriting discounts and commissions and offering expenses.
